HGEN - Humanigen announces it was awarded two patents in U.S.

Humanigen (HGEN) announced that the company was awarded two patents by the United States Patent and Trademark Office (USPTO) covering its lead asset lenzilumab, a recombinant human GM-CSF antagonist.The patent win indicates the value of the company’s approach to neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF), a statement from Humanigen said.The first patent issued in January relates to the use of lenzilumab in reducing non-GM-CSF cytokines/chemokines that can lead to immunotherapy-related toxicity.The second patent issued in February is regarding the use of lenzilumab to improve the efficacy and durability of immunotherapy.In December, Humanigen announced that it received a patent for lenzilumab covering the prevention of cytokine storm and neurotoxicity related to car-t cell therapy.

For further details see:

Humanigen announces it was awarded two patents in U.S.